Calidi Biotherapeutics, Inc. CLDI

SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that on September 21, 2026, the Company received a notice (the “Notice”) from the staff of NYSE American LLC (the "NYSE American") that the Company was not in compliance with the NYSE American's continued listing standards in Part 10, Section 1003(a)(ii)of the NYSE American C

SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it has entered into a definitive stock purchase agreement with certain accredited investors and/or qualified institutional buyers for the purchase and sale of 1,025,640 shares of the Company’s common stock, in a registered direct offering, at a per share purchase price o